CJC-1295 / Ipamorelin (GH Pulse)
Blend of CJC-1295 (GHRH analog) and Ipamorelin (GHRP), studied for growth-hormone-axis support, recovery, and body composition.
This is a combination sold as one vial. It has not been studied as a single substance, so what is known is what is known about each part, linked above. Sources that report a dose for the blend report it for that mixture, not for any component on its own.
We have not published an audit on CJC-1295 / Ipamorelin (GH Pulse). Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
Pairs a GHRH analog (CJC-1295) with a selective GH secretagogue (Ipamorelin) to stimulate pulsatile GH release; studied for recovery and body composition.
CJC-1295 tells the pituitary gland to make growth hormone via the GHRH receptor, while Ipamorelin triggers the actual GH release via a separate ghrelin receptor on the same cells, with the two signals working together to amplify the natural GH pulse.
Reported side effects
Common effects include temporary facial flushing, mild water retention, vivid dreams, slight hunger increase, and injection-site irritation, with more serious concerns including GH-driven cell proliferation risk in those with cancer history, blood sugar changes, and carpal tunnel-style symptoms at excessive doses.
Who should avoid it
People with active or prior cancer, pituitary disease, diabetic retinopathy, severe kidney disease, or who are pregnant or breastfeeding should not use GH-stimulating peptides.
What gets monitored
IGF-1 baseline before starting, then mid-cycle (week 6-8) and 4 weeks post-cycle. Fasting glucose and HbA1c if metabolic risk factors are present. Joint and hand symptoms throughout the cycle. Optional: thyroid panel if running multi-month plans, since long-term GH stimulation studies have flagged hypothyroidism in a minority of users. [Source: peptidedosingprotocols.com]
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for CJC-1295 / Ipamorelin (GH Pulse) or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 200-300 mcg of each peptide (CJC-1295 no DAC and Ipamorelin) daily; lower doses of 100-150 mcg typical for first 2-4 weeks before titration | Once dailyStandard: 8-12 weeks on, 4 weeks off; Extended: 16 weeks on, 8 weeks off; Short test: 4-6 weeks on, 4 weeks off | subcutaneous | peptidedosingprotocols.comWhat it saysHide(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com] |
- Once dailyStandard: 8-12 weeks on, 4 weeks off; Extended: 16 weeks on, 8 weeks off; Short test: 4-6 weeks on, 4 weeks off
- subcutaneous
- peptidedosingprotocols.com
What it saysHide
(secondary reference; provider confirmation required). [Source: peptidedosingprotocols.com]
- For a 20 mg pre-blended vial (10 mg CJC-1295 + 10 mg Ipamorelin): add 3.0 mL bacteriostatic water for a concentration of 6.67 mg/mL total (3.33 mg/mL each peptide); a 200 mcg dose of each peptide = 6 units (0.06 mL) on a U-100 syringe. Alternative fills: 2.0 mL BAC water = 10.0 mg/mL total (5.0 mg/mL each), 200 mcg dose = 4 units (0.04 mL); 2.5 mL BAC water = 8.0 mg/mL total (4.0 mg/mL each), 200 mcg dose = 5 units (0.05 mL). For separate 10 mg vials: add 3.0 mL BAC water to each = 3.33 mg/mL, 200 mcg dose = 6 units (0.06 mL). Step-by-step: inspect the vial; wipe stopper with alcohol prep pad and let dry; draw planned BAC water volume with a sterile syringe; inject BAC water slowly down the inside wall of the vial (do not spray directly onto powder); gently swirl (do not shake) until powder dissolves; label with date and concentration; refrigerate at 35.6-46.4°F (2-8°C) shielded from light; use within 28-30 days; discard if cloudy, discolored, or contaminated.
Common questions
What does the CJC-1295 + Ipamorelin stack do?
It stimulates the body's own growth hormone release through two separate receptor pathways. CJC-1295 (no DAC) hits GHRH receptors on the pituitary, telling the pituitary to make GH. Ipamorelin hits the ghrelin receptor on the same cells, triggering the actual GH pulse. The combination is described in pharmacology literature as synergistic. Neither compound is FDA-approved for any clinical use.
What is the standard CJC-1295 + Ipamorelin dosage?
The most common research-planning range is 100-300 mcg of each peptide, injected subcutaneously once daily on an empty stomach. A typical pre-blended 20 mg vial (10 mg + 10 mg) reconstituted with 3.0 mL bacteriostatic water gives a clean 6-unit insulin draw for 200 mcg of each peptide. This is research-planning context, not a personal dosing recommendation.
Open the reconstitution calculator →Should I use CJC-1295 with or without DAC?
Without DAC for Ipamorelin pairing. The no-DAC variant has a 30-minute to 2-hour half-life that matches Ipamorelin's roughly 2-hour half-life, which preserves the body's natural pulsatile GH release. CJC-1295 with DAC has a 5.8-8.1 day half-life and produces sustained GHRH stimulation that does not pair cleanly with Ipamorelin's pulse-based mechanism.
How is the 20 mg blend reconstituted?
The featured research-planning approach is 3.0 mL of bacteriostatic water, which gives 6.67 mg/mL total concentration (3.33 mg/mL of each peptide). On a U-100 insulin syringe, 3 units delivers 100 mcg of each peptide, 6 units delivers 200 mcg, and 9 units delivers 300 mcg.
Check 20 mg in 3 mL in the calculator →How long is a typical cycle?
Most research-planning cycles run 8-12 weeks on, followed by 4 weeks off. Extended plans go 16 weeks on, 8 weeks off. Off-cycle periods are commonly described as a way to reduce the chance of receptor desensitization with sustained ghrelin-receptor stimulation. Long-term safety beyond 90 days has not been studied for the combined blend.
What are the main side effects?
Commonly reported: temporary facial flushing, mild water retention in the first 1-2 weeks, vivid dreams, deeper sleep, and a small post-injection hunger bump from Ipamorelin. Concerns that require attention: carpal tunnel-style tingling (signals excessive GH/IGF-1), elevated fasting glucose, persistent joint pain, and rare immunogenicity reactions. Anyone with active or prior cancer, pituitary disease, diabetic retinopathy, severe kidney disease, or pregnancy should not use GH-stimulating peptides.
Are CJC-1295 and Ipamorelin FDA-approved?
No. As of June 2026, neither compound is FDA-approved for any clinical use. Both were placed on FDA Category 2 in September 2023, removed in September 2024 after withdrawn nominations, and reviewed by PCAC in late 2024 with FDA recommending against 503A Bulks inclusion. Reclassification discussions in 2026 are ongoing but no formal change has been published.
Is there direct human research on the CJC-1295 + Ipamorelin blend?
No published human randomized trial has tested the CJC-1295 (no DAC) + Ipamorelin combination at the daily 200-300 mcg doses common online. The case for the stack rests on each compound's individual human pharmacokinetic data plus cellular and animal evidence that the two pathways are synergistic on the same pituitary cell.
Sources
The reference sections above are imported from our compound knowledge base, which classes the evidence for CJC-1295 / Ipamorelin (GH Pulse) as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.
Sermorelin is a synthetic 29-amino-acid analog of growth-hormone-releasing hormone (GHRH) studied in growth-hormone axis research.
Blend of Tesamorelin (GHRH analog) and Ipamorelin (GHRP), studied for GH-axis support, visceral fat, and recovery.
Glutathione is a tripeptide antioxidant central to cellular redox biology research.
5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.
Peptide bioregulator referenced for connective tissue support.